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 ABSTRACT 
Although there is a significant effort in the discovery of effective therapies to contrast both the 
pathological endocrine and metabolic aspects of diabetes and the endothelial dysfunction associated 
with this disease, no hypoglycemic drug has been proven to defeat the cardiovascular complications 
associated with type II diabetes. The aim of this research was to design new compounds exhibiting 
a double profile of hypoglycemic agents/NO-donors. The synthesis of molecules obtained by the 
conjunction of NO-donor moieties with two oral insulin-secretagogue drugs (repaglinide and 
nateglinide) was reported. NO-mediated vasorelaxing effects of the synthesised compounds were 
evaluated by functional tests on isolated endothelium-denuded rat aortic rings. The most potent 
molecule (4) was tested to evaluate the hypoglycaemic and the anti-ischemic cardioprotective 
activities. This study indicate that 4 should represent a new insulin-secretagogue/NO-donor prodrug 
with an enhanced cardiovascular activity, which may contrast the pathological aspects of diabetes 
and endowed of cardioprotective activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Type II diabetes mellitus is a multifactorial disease characterized by a combination of insulin 
resistance and reduced insulin secretion.  The impact of this disease on social health is closely 
linked to the co-existence of both metabolic and cardiovascular disorders.1 It is well-known that the 
endothelial dysfunction is responsible for important macro-vascular problems such as myocardial 
ischemia, hypertension and peripheral vasculopathy. Lately, heart diseases and stroke are the main 
causes of death and disability among people with type 2 diabetes. 2  
Structural and functional alterations of vascular structures, such as the glycation of wall 
components of blood vessels, are strongly involved in the pathogenesis of cardiovascular 
complications associated with diabetes. One of the major vascular alterations is the endothelial 
dysfunction, resulting in a relevant imbalance in the production of endothelium-derived endogenous 
factors pivotally involved in the regulation of the cardiovascular function. In particular, it is well 
known that diabetes is associated with a significant reduction in the biosynthesis and release of 
endothelial nitric oxide (NO). 3 
NO is an  important endothelium-derived mediator endowed of vasodilator, anti-platelet, anti-
proliferative, permeability-decreasing and anti-inflammatory properties.4 An impairment of 
endothelium-dependent vasorelaxation caused by a reduced NO activity, worsens the diabetic 
metabolic alterations (dyslipidaemia, glycation end-products, oxidative stress), thus resulting in a 
dramatically prevalence of atherosclerosis, thrombosis, vascular inflammation and remodeling, 
hypertension, coronaropathy and stroke.5,6 
Therefore, in order to reduce the cardiovascular risk, diabetic patients usually follow additional 
pharmacological treatments targeting hypertension, platelet aggregation, and dyslipidaemia.6,7  
In the last years, the development of new ‘chimeras’, with the double pharmacodynamic profile 
of hypoglicemic agents and, at the same time, of slow NO donors, has been first reported by us and 
then widely investigated.8-10 NO-sulfonylureas and NO-meglitinides2,8,11  are interesting examples of 
drugs able to contrast both the endocrine and the cardiovascular complications of diabetes mellitus. 
These “chimeric drugs” conserved the antidiabetic properties, due to their insulin-secretagogue 
activity; moreover, they were endowed of additional NO-releasing property. Such an ability to 
release exogenous NO was considered as an intriguing pharmacological approach, aimed at 
counterbalancing the reduced availability of endogenous NO in the diabetic patients, and thus at 
attenuating the diabetes-associated cardiovascular complications. Indeed, the meglitinides 
repaglinide (REP) and nateglinide (NAT) are non-sulfonylurea insulin secretagogue drugs, effective 
in treating type 2 diabetes.12  Like sulfonylureas, these drugs stimulate insulin secretion by blocking 
the ATP-sensitive potassium channels (KATP) in pancreatic β cells, thus  improving overall 
glycemic control. REP and NAT inhibit also KATP channels of cardiomyocytes, and vascular 
smooth muscle cells,13,14 and this may contribute to the onset of cardiovascular complications.15  
As a further development of our work on the design of new NO-donor antidiabetics,8 we describe 
a new class of NO-donor hybrids obtained by coupling REP and NAT with appropriate NO-
releasing moieties,16 aiming at improving the pharmacological profile (Figure 1). In particular, this 
paper describes the synthesis of new multifunctional insulin-secretagogue/NO-donor derivatives 
and the evaluation of both the NO-mediated vasorelaxing effects on isolated rat aortic rings and the 
in vivo hypoglycemic properties. Moreover, the cardioprotective and hypoglicaemic activities of the 
most active compound 4 (namely, NO-NAT) were evaluated. 
 
2. Results and discussion 
2.1 Chemistry 
The new compounds were prepared by the coupling of the carboxylic function of REP and NAT 
with a NO-donor moiety through an in vivo hydrolysable ester bond.  The NO-releasing groups 
involved in this study have already been used for the synthesis of other class of NO-donor drugs.16 
In particular 3-nitrooxymethylbenzyl alcohol- (8a), 4-nitrooxymethylbenzyl alcohol- (8b), 3-[1-
(nitrooxy)ethyl]benzyl alcohol, and 4-[1-(nitrooxy)ethyl]benzyl alcohol were chosen as linker 
groups because of their different NO-releasing rate.16  The NO donor-meglitinide derivatives NO-
REP (1,2) and NO-NAT (3,4), were synthesised by condensation of REP or NAT, respectively, 
with the appropriate nitrooxymethylbenzyl alcohol (8a,b)17 in the presence of DCC and a catalytic 
amount of DMAP in DCM (Scheme 1). The meta- and para- [(1-nitrooxy)ethyl]benzyloxy 
derivatives 5 and 6 were prepared, as shown in Scheme 2. The 3-(1-hydroxyethyl)benzyl alcohol 
(9a) or 4-(1-hydroxyethyl)benzyl alcohol (9b), obtained by reduction of the appropriate acetyl 
benzoic acid, was condensed with REP in the presence of DCC and a catalytic amount of DMAP 
affording the product (10,11). The subsequent reaction of the alcohol 10,11 with HCl in toluene 
gave the corresponding chloride and the nitration with AgNO3 afforded to the products 5 and 6. 
Compound 7 was obtained starting from NAT and following the same synthetic procedure 
described above for compounds 5 and 6.  
 
2.2 Pharmacology 
2.2.1 Evaluation of NO-releasing properties. 
The prodrugs 2 and 4  induced almost full vasorelaxing effects (Emax = 94 ± 4 and 93 ± 1, for 2 
and 4, respectively; Table 1) which were strongly inhibited by 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ) 1μM, an inhibitor of guanylate cyclase, as expected in the case of an 
NO-mediated effect. The shifting of the nitrooxymethyl-group from the para (2,4) to the meta 
position (1,3) in both NAT and REP derivatives reduced the vasorelaxing efficacy; such a reduction 
is more marked in the NAT-derivatives with respect to the REP-derivatives (Table 1). The same 
effect has been also observed for 5-7 compounds in which a methyl group has been added at the 
alpha-position of nitrooxy-group.  
 
 
2.2.2 Evaluation of hypoglicaemic properties.  
Since the essential issue for an insulin-secretagogue/NO-donor hybrid is the retention of its 
hypoglycaemic activity, we selected the NO-NAT derivative 4, which showed the best vasorelaxing 
profile,  to further investigate its activity on the glucose metabolism. As shown in figure 2, when 
compared to the normoglycaemic animals, the diabetic rats showed a significantly higher increase 
of glycaemic levels, following the administration of glucose. The glycaemic pattern shown by 
diabetic animals submitted to acute pre-treatment with NAT or with an equivalent dose of 4 was 
almost superimposable to that exhibited by normoglycaemic animals, indicating that NAT and the 
hybrid compound 4 are endowed with almost equivalent insulin-secretagogue activity (Figure 2). 
 
2.2.3 Cardio-protective anti-ischemic effects. 
In order to evaluate if the new multifunctional insulin-secretagogue/NO-donor derivative 4 was 
provided of  additional beneficial cardiovascular activity, the effect induced by 4 on Langendorff-
perfused diabetic rat hearts subjected to an ischemia-reperfusion cycle was evaluated. As indicated 
in figure 3, the ischemia/reperfusion injury in the hearts from diabetic rats (decrease of RPP and  
presence of ischemic areas) was almost equivalent to that observed in hearts from normoglycaemic 
animals. Pre-treatment with nateglinide determined a slight and not significant improvement of the 
parameters. Pre-treatment with 4 promoted a cardio-protective effect, determining an evident (albeit 
not statistically significant) reduction of the ischemic areas and a marked and a statistically 
significant (P < 0.01) improvement of the post-ischemic recovery of functional parameter (RPP).  
 
3. Conclusion 
In the last decade, the development of “chimeric drugs” has been one of the most exciting fields 
of investigation. The addition of NO-releasing properties has been a widely used strategy in the 
design of such “chimeras”, in order to improve the overall pharmacotherapeutic impact of a given 
drug and/or to reduce the adverse effects.9,10 Since the reduced biosynthesis of endogenous NO is a 
typical feature in diabetes (leading to the well-known diabetes-associated cardiovascular 
complications),1 the addition of NO-releasing properties to antidiabetic agents seems to be a 
winning strategy for projecting “chimeric” drugs able to target both the metabolic dysfunction and, 
at the same time, the vascular complications.2,8 Indeed, this work reported effective NO-antidiabetic 
molecules, combining the hypoglycaemic activity of meglitinides and NO-mediated cardiovascular 
properties, due to the conjugation of the insulin secretagogue drugs NAT and REP with opportunely 
spaced nitrooxy function, which is one of the most versatile and reliable NO-releasing moiety.  In 
particular, the NO-NAT derivative 4, selected as the lead compound in this experimental work, was 
endowed of satisfactory hypoglycaemic effects, comparable to those exhibited by the “parent drug” 
NAT. Moreover, the presence of the NO-releasing feature conferred on this dual drug vasorelaxing 
and cardioprotective effects, which seem to be an extremely useful improvement of the 
pharmacological profile. Besides the improved cardiovascular profile, it is noteworthy that the risk 
of excessive hypoglicaemia (i.e., the typical side-effect of insulin-secretagogues) is likely to be 
lower in meglitinides than in sulphonylureas.18 However, no specific test has been carried out in this 
study. The evaluation of the possible toxicity of the new NO-meglitinides reported in this study, as 
well as the investigation of further NO-mediated useful effects, such as the antiplatelet and the 
antihypertensive ones, will be the object of future experimental work. 
 
4. Experimental section 
4.1 Chemistry  
1H NMR spectra of all compounds were obtained with a Gemini 200 spectrometer operating at 
200 MHz (for compounds 6, 9-15) or with a Bruker TopSpin 3.2 400 MHz spectrometer (for 
compounds 1-5, 7). 13C NMR spectra were fully decoupled. The following abbreviations are used: 
singlet (s), doublet (d), triplet (t), multiplet (m) and broad signal (br s). Chemical shifts () are 
reported in parts per million downfield from tetramethylsilane and referenced from solvent 
references. Analytical TLCs were carried out on 0.25 mm layer silica gel plates containing a 
fluorescent indicator; spots were detected under UV light (254 mn). Column chromatography was 
performed using 70-230 mesh silica gel. Infrared (IR) spectra were obtained using a Agilent 660 
with  ATR Pike spectrophotometer. Data are presented as frequency of absorption (cm-1). Mass 
spectra were obtained on a Hewlett-Packard 5988 A spectrometer using a direct injection probe and 
an electron beam energy of 70 eV. Evaporation was performed in vacuo (rotating evaporator); 
sodium sulfate was always used as drying agent. Elemental analyses were performed in our 
analytical laboratory and agreed with the theoretical values to within ± 0.4%. 
4.1.1  3-nitrooxymethyl-benzoate of repaglinide 1 
A solution of repaglinide (300 mg, 0.66 mmol), 3-(nitrooxymethyl)-benzylalcohol 8a (121 mg, 
0.66 mmol), DCC (164 mg, 0.79 mmol) and DMAP (7 mg) in CH2Cl2 (13 mL) was stirred at room 
temperature for 3h. The suspension  was then filtered off and the solvent evaporated to give a crude 
residue which was purified by column chromatography eluting with hexane/AcOEt (7:3). The solid 
obtained was then mashed with hexane provided compound 1 (162 mg, 0.26 mmol, 39%). 1H-NMR 
(CDCl3):  0.91 (d, 6H, J = 4.0 Hz, CH3), 1.37 (t, 3H, J = 7.0 Hz, OCH2CH3), 1.49-1.70 (m, 9H, 
CH2, CH), 2.54-2.65 (m, 2H, CH2N), 2.86-2.97 (m, 2H, CH2N), 3.53 (s, 2H, CH2CONH), 3.94-4.07 
(m, 2H, OCH2CH3), 5.30-5.38 (m, 1H, CHNH), 5.34 (s, 2H, CH2O), 5.43 (s, 2H, CH2ONO2), 6.69 
(d, 1H, J = 8.6 Hz, Ar), 6.78-6.86 (m, 2H, Ar), 7.05-7.07 (m, 2H, Ar), 7.16-7.19 (m, 2H, Ar), 7.37-
7.48 (m, 4H, Ar), 7.78 (d, 1H, J = 7.7 Hz, NH). 13C NMR (CDCl3): δ 14.73 (CH3), 22.62 (CH3), 
22.86 (CH), 24.22 (CH2), 25.43 (CH2, pip), 26.84 (CH2, pip), 44.32 (CH2CO), 46.77 (CH2O), 49.90 
(CHNH), 64.60 (CH2N, pip), 66.02 (OCH2), 74.64 (CHONO2), {113.91, 118.70, 120.92, 122.90, 
125.17, 127.48, 128.03, 128.65, 128.78, 129.15, 129.23, 132.44, 132.61, 137.25, 138.75, 141.70, 
152.61, 159.12} (Ar), 166.03 (COO), 168.81 (CONH)  ppm. Anal. (C35H43N3O7) C, H, N % Calcd: 
68.07 (C); 6.97 (H); 6.81 (N). % Found: 68.28 (C); 7.23 (H); 6.77 (N). 
4.1.2 4-nitrooxymethyl-benzoate of repaglinide 2 
The repaglinide 4-(nitrooxymethyl)benzoate was synthesized from 4-
(nitrooxymethyl)benzylalcohol 8b (121 mg, 0.66 mmol) following the same procedure described 
above for the preparation of  the repaglinide 3-(nitrooxymethyl)benzoate (1). This compound was 
purified by column chromatography eluting with hexane/AcOEt (7:3) and then by precipitation with 
n-hexane from AcOEt to give compound 2 (154 mg, 0.25 mmoli, 38%). FTIR (neat) ν 3273 (NH), 
2931 (Ar), 1699 (CO), 1640 (NO2), 1277 (NO2), 1252 (OEt) cm−1; 1H-NMR (CDCl3):  0.91 (d, 
6H, J = 4.0 Hz, CH3), 1.37 (t, 3H, J = 8.0 Hz, OCH2CH3), 1.49-1.59 (m, 9H, CH2, CH ), 2.57-2.65 
(m, 2H, CH2N), 2.86-2.98 (m, 2H, CH2N), 3.53 (s, 2H, CH2CONH), 3.95-4.10 (m, 2H, OCH2CH3), 
5.30-5.39 (m, 1H, CHNH), 5.34 (s, 2H, CH2O), 5.43 (s, 2H, CH2ONO2), 6.73-6.74 (m, 1H, Ar), 
6.82-6.86 (m, 2H, Ar), 7.05-7.08 (m, 2H, Ar), 7.18-7.20 (m, 2H, Ar), 7.40 (d, 2H, J = 8.0 Hz, 
AA’XX’), 7.49 (d, 2H, J = 8.0 Hz, AA’XX’), 7.78 (d, 1H, J = 8.0 Hz, NH ). 13C NMR (CDCl3): δ 
14.79 (CH3), 22.66 (CH3), 22.88 (CH), 24.25 (CH2), 25.46 (CH2, pip), 26.87 (CH2, pip), 44.38 
(CH2CO), 46.79 (CH2O), 49.96 (CHNH), 64.63 (CH2N, pip), 66.98 (OCH2), 74.55 (CHONO2), 
{113.90, 118.74, 120.94, 122.95, 125.20, 127.82, 128.05, 128.51, 129.32, 132.11, 132.48, 137.90, 
138.78, 141.70, 152.64, 159.15} (Ar), 166.04 (COO), 168.78(CONH) ppm. Anal. (C35H43N3O7) C, 
H, N. % Calcd: 68.07 (C); 6.97 (H); 6.81 (N). % Found: 67.82 (C); 6.68 (H); 6.45 (N). 
4.1.3 3-nitrooxymethylbenzoate of nateglinide 3 
A solution of nateglinide (200 mg, 0.63 mmol) in CH2Cl2 (12 mL), 3-(nitroxymethyl) 
benzylalcohol 8a (115 mg, 0.63 mmol), DCC ( 156 mg, 0.75 mmol) and DMAP (6 mg) was stirred 
at room temperature for 3h. The mixture was then filtered off and the organic layer evaporated to 
give a crude residue which was purified by column chromatography eluting with hexane/AcOEt 
(7:3). The product was then crystallized from AcOEt/hexane obtained compound 3 (98 mg, 0.20 
mmol, 32%). mp: 93-95 °C, 1H NMR (CDCl3): δ 0.85 (d, 6H, J = 4.0 Hz, CH3), 0.94-1.04 (m, 3H, 
cyclohexyl), 1.25-1.42 (m, 3H, cyclohexyl), 1.75-2.03 (m, 5H, cyclohexyl), 3.07-3.17 (m, 2H, 
CH2Ph), 4.90-4.96 (m, 1H, CHNH), 5.11-5.18 (m, 2H, CH2O), 5.42 (s, 2H, CH2ONO2), 5.87 (d, 
1H, J = 8.0 Hz, NH), 6.95-7.05 (m, 2H, Ar), 7.21-7.39 (m, 7H, Ar). 13C NMR (CDCl3): δ 19.85 
(CH3), {29.02, 29.10, 29.63, 29.88} (cyclohexyl), 32.89 (CH), 38.03 (CH2Ph), 43.34 (CH), 45.60 
(CHCO), 52.89 (CHCOO), 66.74 (CH2O), 74.48 (CH2ONO2), {127.23, 128.66, 129.14, 129.24, 
129.36, 129.45, 129.67, 132.87, 135.87, 136.09} (Ar), 171.76 (CONH), 175.78 (COO) ppm. [α] (in 
MeOH 1.0%) = -1.7. Anal. (C27H34N2O6) C, H, N. % Calcd: 67.20 (C); 7.10 (H); 5.80 (N). % 
Found: 67.08 (C); 6.87 (H); 5.55 (N). 
 
 
4.1.4 4-(nitroxymethyl)benzoate of  nateglinide 4 
The nateglinide 4-(nitrooxymethyl)benzoate was synthesized from 4-
(nitrooxymethyl)benzylalcohol 8b (231 mg, 1.26 mmoli) following the same procedure described 
above for the preparation of  the nateglinide 3-(nitrooxymethyl)benzoate (3). This compound was 
purified by column chromatography eluting with AcOEt/hexane (8:2) and then by precipitation with 
n-hexane from AcOEt to give compound 4 (140 mg, 0.29 mmol, 23%). mp: 115-117 °C, IR (neat): 
ν 3299 (NH), 2928 (Ar), 1737 (CO), 1640 (NO2), 1277 ( NO2) cm−1; 1H NMR (CDCl3): δ 0.85 (d, 
6H, J = 4.0 Hz, CH3), 0.90-1.06 (m, 3H, cyclohexyl), 1.26-1.42 (m, 3H, cyclohexyl), 1.75-1.78 (m, 
2H, cyclohexyl), 1.83-1.89 (m, 2H, cyclohexyl), 1.96-2.04 (m, 1H, CH), 3.06-3.17 (m, 2H, CH2Ph), 
4.90-4.95 (m, 1H, CHNH), 5.12 (d, 1H, J = 14.0 Hz, CH2O), 5.17 (d, 1H, J = 14.0 Hz, CH2O), 5.43 
(s, 2H, CH2ONO2), 5.89 (d, 1H, J = 8.0 Hz, NHCH), 6.99-7.01 (m, 2H, Ar), 7.21-7.23 (m, 3H, Ar), 
7.32 (d, 2H, J = 8.0 Hz, AA’XX’), 7.39 (d, 2H, J = 8.0 Hz, AA’XX’) ppm. 13C NMR (CDCl3): δ 
19.89 (CH3), {29.15, 29.22, 29.75, 30.00} (cyclohexyl), 33.01 (CH), 38.11 (CH2Ph), 43.46 (CH), 
45.72 (CHCO), 53.00 (CHCOO), 66.79 (CH2O), 74.51 (CH2ONO2), {127.36, 128.78, 129.13, 
129.51, 129.57, 132.81, 135.98, 136.77} (Ar), 171.86 (CONH), 175.90 (COO) ppm. MS (m/z): 482 
(M+, 70%), 439 (M+ -(CH3)2CH, 100%). Anal. (C27H34N2O6) C, H, N. % Calcd: 67.20 (C); 7.10 
(H); 5.80 (N). % Found: 67.14 (C); 6.99 (H); 5.67 (N). 
 4.1.5 3-[1-(nitrooxy)ethyl]benzoate of repaglinide 5 
AgNO3 (201 mg, 1.19 mmol) was added to a stirred solution of of 3-[1-(chloroethyl]benzoate of 
repaglinide (12) (184 mg, 0.30 mmol) in CH3CN (1.1 mL). Stirring was continued over 4h at rt in 
the dark, and then the precipitate (silver chloride) was filtered off and the solvent was evaporated. 
The crude product was purified by column chromatography eluting with hexane/AcOEt (7:3) to 
give 5 (30 mg, 0.05 mmol, 16 % yield) as a white solid: 1H-NMR (CDCl3):  0.91 (d, 6H, J = 4.0 
Hz, CH3), 1.22-1.26 (m, 2H, CH2), 1.37 (t, 3H, J = 7.0 Hz, OCH2CH3), 1.50-1.70 (m, 10H, CH2, 
CH, CH3), 2.55-2.65 (m, 2H, CH2N), 2.86-2.97 (m, 2H, CH2N), 3.53 (s, 2H, CH2CONH), 3.97-4.06 
(m, 2H, OCH2CH3), 5.30-5.42 (m, 1H, CHNH), 5.34 (s, 2H, CH2O), 5.94 (q, 1H, J = 4.0 Hz, 
CHCH3), 6.71 (d, 1H, J = 8.0 Hz, Ar), 6.81-6.86 (m, 2H, Ar), 7.05-7.07 (m, 2H, Ar), 7.16-7.22 (m, 
2H, Ar), 7.33-7.46 (m, 4H, Ar), 7.79 (d, 1H, J = 8.0 Hz, NH) ppm. 13C NMR (CDCl3): δ 14.79 
(CH3), 20.52 (CH3), 22.68 (CH3), 22.91 (CH2), 24.26 (CH), 25.47 (CH2, pip), 26.90 (CH2, pip), 
29.85 (CH), 44.43 (CH2CO), 46.80 (CH2O), 64.66 (CH2N, pip), 66.19 (OCH2), 81.91(CHONO2), 
{113.95, 120.98, 122.82, 125.26, 125.98, 126.03, 127.75, 127.77, 128.09, 128.82, 129.21, 132.50, 
137.20, 138.77, 139.17,  141.67, 152.66, 159.16} (Ar), 165.96 (COO), 168.70 (CONH). Anal. 
(C31H36N2O7) C, H, N. % Calcd: 68.44 (C); 7.18 (H); 6.65 (N). % Found: 68.57 (C); 7.46 (H); 6.98 
(N). 
4.1.6  4-[1-(nitrooxy)ethyl]benzoate of repaglinide 6 
AgNO3 (827 mg, 4.87 mmol) was added to a stirred solution of of 4-[1-(chloroethyl]benzoate of 
repaglinide (11) (752 mg, 1.24 mmol) in CH3CN (10 mL). Stirring was continued over 4h at rt in 
the dark, and then the precipitate (silver chloride) was filtered off and the solvent was evaporated. 
The crude product was purified by column chromatography eluting with hexane/AcOEt (7:3) to 
give 6 (156 mg, 0.25 mmol, 20 % yield): 1H-NMR (CDCl3):  0.91 (d, 6H, J = 6.7 Hz, CH3); 1.25-
1.64 (m, 12H, CH2, CH, CH3); 1.37 (t, 3H, J = 7.0 Hz, OCH2CH3); 2.55-2.65 (m, 2H, CH2N); 2.86-
2.97 (m, 2H, CH2N); 3.53 (s, 2H, CH2CONH); 3.94-4.06 (m, 2H, OCH2CH3); 5.30-5.42 (m, 1H, 
CHNH); 5.33 (s, 2H, CH2O); 5.93 (q, 1H, J = 6.7 Hz, CHCH3); 6.70 (d, 1H, J = 8.1 Hz, Ar); 6.81-
6.85 (m, 2H, Ar); 7.02-7.10 (m, 2H, Ar); 7.16-7.50 (m,6H, Ar); 7.79 (d, 1H, J = 7.7 Hz, NH). 13C 
NMR (CDCl3): δ 14.87 (CH3), 22.75 (CH3), 22.97 (CH3), 24.39 (CH2), 25.63 (CH2, pip), 26.99 
(CH2, pip), 34.15 (CH), 44.94 (CH2CO), 46.93 (CH2O), 49.97 (CHNH), 55.26 (CH2N, pip), 58.57 
(OCH2), 64.87 (CHONO2), {113.54, 114.23, 120.99, 122.84, 125.19, 125.61, 126.41, 126.48 
127.27, 127.78, 128.03, 128.42, 132.35, 138.90} (Ar), 159.50 (COO) 169.00 (CONH). Anal. 
(C31H36N2O7) C, H, N. % Calcd: 68.44 (C); 7.18 (H); 6.65 (N). % Found: 68.72 (C); 7.39 (H); 6.74 
(N). 
 
4.1.7  4-[1-(nitrooxy)ethyl]benzoate of nateglinide 7 
AgNO3 (991 mg, 5.84 mmol) was added to a stirred solution of of 4-[1-(chloroethyl]benzoate of 
nateglinide (15) (700 mg, 1.49 mmol) in CH3CN (8 mL). Stirring was continued over 4h rt in the 
dark, and then the precipitate (silver chloride) was filtered off and the solvent was evaporated. The 
crude product was purified by column chromatography eluting with hexane/AcOEt (7:3) to give 7 
(185 mg, 0.37 mmol, 25 % yield) as a white solid: mp: 80-82 °C, 1H-NMR (CDCl3): δ 0.85 (d, 6H, 
J = 4.0 Hz, 2 CH3), 0.91-1.06 (m, 3H, cyclohexyl), 1.33-1.42 (m, 3H, cyclohexyl), 1.63 (d, 3H, J = 
4.0 Hz, CH3), 1.75-1.78 (m, 2H, cyclohexyl), 1.83-1.88 (m, 2H, cyclohexyl), 1.96-2.03 (m, 1H, 
CHCH3),  3.07-3.17 (m, 2H, CH2Ph), 4.90-4.96 (m, 1H, CHNH), 5.12 (d, 1H, J = 14.0 Hz, CH2O), 
5.17 (d, 1H, J = 14.0 Hz, CH2O), 5.89 (d, 1H, J = 8.0 Hz, NHCH), 5.94 (q, 1H, J = 4.0 Hz, 
CHONO2), 6.96-7.01 (m, 2H, Ar), 7.21- 7.22 (m, 3H, Ar); 7.31 (d, 2H, J = 8.2 Hz, AA’XX’); 7.38 
(d, 2H, J = 8.2 Hz, AA’XX’) ppm. 13C NMR (CDCl3): δ 19.91 (CH3), 20.54 (CH3), {29.08, 29.16, 
29.68, 29.94} (cicloesil), 32.95 (CH), 38.04 (CH2Ph), 43.40 (CH), 45.66 (CH-CONH), 52.91 
(CHCOO), 66.79 (CH2O), 81.71 (CHONO2), {126.67, 127.28, 128.69, 129.17, 129.52, 135.92, 
136.11, 139.29} (Ar), 171.80 (CONH), 175.80 (COO) ppm. Anal. (C28H36N2O6) C, H, N. % Calcd: 
67.34 (C); 6.91 (H); 5.82 (N). % Found: 67.58 (C); 6.95 (H); 6.05 (N). 
 
4.1.8  3-(1-hydroxyethyl)benzyl alcohol 9a 
A solution of 3-acetylbenzoic acid  (500 mg; 3.05 mmol) in THF (3 mL) was added to a 
solution of LiAlH4 1M in THF (230 mg; 6.09 mmol) cooled at 0 °C. The mixture was stirred at 0 °C 
for 12h, then water (1.7 mL) and NaOH 1M (0.4 mL) was added, and the resulting suspension 
filtrated. The solvent was evaporated to give 9a (432 mg, 2.84 mmol, 93 % yield) as a yellow oil: 
1H NMR (CDCl3): δ 1.46 (d, 3H, J = 6.5 Hz, CH3); 4.63 (s, 2H, CH2OH); 4.85 (q, 1H, J = 6.5 Hz, 
CH); 7.20-7.35 ppm (m, 4H, Ar). 
 
4.1.9 4-(1-hydroxyethyl)benzyl alcohol 9b 
A solution of 4-acetylbenzoic acid  (1 g; 6.10 mmol) in THF (6 mL) was added to a solution of 
LiAlH4 1M in THF (691 mg; 18.29 mmol) cooled at 0 °C. The mixture was stirred at 0 °C for 12h, 
then water (5 mL) and NaOH 1M (1.3 mL) was added, and the resulting suspension filtrated. The 
solvent was evaporated to give 9b (899 mg, 5.92 mmol, 97 % yield) as a yellow oil: 1H NMR 
(CDCl3): δ 1.48 (d, 3H, J = 6.4 Hz, CH3); 4.66 (s, 2H, CH2OH); 4.88 (q, 1H, J = 6.4 Hz, CH); 7.29-
7.38 ppm (m, 4H, Ar)  
.  
 
4.1.10 3-[1-(hydroxyethyl]benzoate of repaglinide 10 
To a solution of 3-(1-hydroxyethyl)benzyl alcohol (9a) (168 mg, 1.11 mmol) in CH2Cl2 (22 mL) 
was added repaglinide (500 mg, 1.11 mmol), DCC (273 mg, 1.32 mmol) and DMAP (11 mg). The 
resulting suspension was stirred at rt for about 4h, then the precipitate was removed by filtration and 
the filtrate was concentrated, to give 10 (583 mg, 0.99 mmol, 90 % yield) as a colorless oil: 1H-
NMR (CDCl3):  0.90 (d, 6H, J = 6.2 Hz, CH3); 1.37 (t, 3H, J = 7.0 Hz, OCH2CH3); 1.48-1.89 (m, 
12H, CH2, CH, CH3); 2.54-2.65 (m, 2H, CH2N); 2.86-2.97 (m, 2H, CH2N); 3.52 (s, 2H, 
CH2CONH); 3.94-4.10 (m, 2H, OCH2CH3); 4.91 (q, 1H, J = 6.2 Hz, CHCH3); 5.28-5.38 (m, 1H, 
CHNH); 5.33 (s, 2H, CH2O); 6.68 (d, 1H, J = 8.2 Hz, Ar); 6.80-6.84 (m, 2H, Ar); 7.05-7.44 (m,8H, 
Ar); 7.70-7.80 (m,1H, NH). Anal. (C36H46N2O5) C, H, N. % Calcd: 73.69 (C); 7.90 (H); 4.77 (N). % 
Found: 73.58 (C); 7.95 (H); 5.05 (N). 
 
 
4.1.11  4-[1-(hydroxyethyl]benzoate of repaglinide 11 
To a solution of 4-(1-hydroxyethyl)benzyl alcohol (235 mg, 1.55 mmol) in CH2Cl2 (5 mL) was 
added repaglinide (700 mg, 1.55 mmol), DCC (383 mg, 1.86 mmol) and DMAP (15 mg). The 
resulting suspension was stirred at rt for about 4h, then the precipitate was removed by filtration and 
the filtrate was concentrated, to give 11 (817 mg, 1.39 mmol, 90 % yield) as a colorless oil: 1H-
NMR (CDCl3):  0.90 (d, 6H, J = 6.3 Hz, CH3); 1.37 (t, 3H, J = 6.6 Hz, OCH2CH3); 1.16-1.80 (m, 
12H, CH2, CH, CH3); 2.54-2.65 (m, 2H, CH2N); 2.86-2.97 (m, 2H, CH2N); 3.52 (s, 2H, 
CH2CONH); 3.93-4.05 (m, 2H, OCH2CH3); 4.91 (q, 1H, J = 6.3 Hz, CHCH3); 5.29-5.42 (m, 1H, 
CHNH); 5.31 (s, 2H, CH2O); 6.71 (d, 1H, J = 8.4 Hz, Ar); 6.79-6.83 (m, 2H, Ar); 7.01-7.10 (m, 2H, 
Ar); 7.15-7.23 (m, 2H, Ar); 7.35-7.44 (m, 4H, Ar); 7.77 (m,1H, NH). Anal. (C36H46N2O5) C, H, N. 
% Calcd: 73.69 (C); 7.90 (H); 4.77 (N). % Found: 73.47 (C); 8.02 (H); 4.89 (N). 
 
 
4.1.12   3-[1-(chloroethyl]benzoate of repaglinide 12 
HClconc. (0.32 mL) was added at room temperature to a stirred suspension of 3-[1-
(hydroxyethyl]benzoate of repaglinide (10) (356 mg, 0.61 mmol) in toluene (3 mL). The  resulting 
solution was stirred for 20h at room temperature. Then, the solvent was evaporated to afford 12 as a 
colorless oil (295 mg, 0.48 mmol, 80 % yield): 1H NMR (CDCl3):  0.87-0.99 (m, 6H, CH3); 1.20-
2.11 (m, 15H, CH2, CH, CH3); 2.62-2.70 (m, 2H, CH2N); 3.07-3.43 (m, 2H, CH2N); 3.67-3.82 (m, 
2H, CH2CONH); 4.00-4.17 (m, 2H, OCH2CH3); 4.60-4.71 (m, 1H, CHNH); (q, 1H, J = 7.0 Hz, 
CHCH3); 5.30 (s, 2H, CH2O); 6.70-6.73 (m, 1H, Ar); 6.90-7.68 (m, 10H, Ar); 7.89-8.00 (m,1H, 
NH). Anal. (C36H45Cl N2O4) C, H, N. % Calcd: 71.44 (C); 7.49 (H); 4.63 (N). % Found: 71.56 (C); 
7.71 (H); 4.80 (N). 
 
 
4.1.13 4-[1-(chloroethyl]benzoate of repaglinide 13 
HClconc. (1 mL) was added at room temperature to a stirred suspension of 4-[1-
(hydroxyethyl]benzoate of repaglinide (11) (1.12 g, 1.91 mmol) in toluene (7 mL). The  resulting 
solution was stirred for 20h at room temperature. Then, the solvent was evaporated to afford 13 as a 
colorless oil (752 mg, 1.24 mmol, 65 % yield): 1H NMR (CDCl3):  0.85-0.99 (m, 6H, CH3); 1.30-
2.08 (m, 15H, CH2, CH, CH3); 2.58-2.68 (m, 2H, CH2N); 3.00-3.08 (m, 2H, CH2N); 3.75 (s, 2H, 
CH2CONH); 3.94-4.08 (m, 2H, OCH2CH3); 4.60-4.71 (m, 1H, CHNH); 5.08 (q, 1H, J = 6.8 Hz, 
CHCH3); 5.28 (s, 2H, CH2O); 6.71-6.74 (d, 1H, J = 6.2 Hz, Ar); 6.89 (d, 1H, J = 7.7 Hz, Ar); 7.08 
(s, 1H, Ar); 7.17-7.66 (m, 8H, Ar); 7.83-7.86 (m,1H, NH). Anal. (C36H45Cl N2O4) C, H, N. % 
Calcd: 71.44 (C); 7.49 (H); 4.63 (N). % Found: 71.22 (C); 7.19 (H); 4.53 (N). 
 
 
4.1.14  4-[1-(hydroxyethyl]benzoate of nateglinide 14 
To a solution of 4-(1-hydroxyethyl)benzyl alcohol (335 mg, 2.21 mmol) in CH2Cl2 (5 mL) was 
added nateglinide (700 mg, 2.21 mmol), DCC (547 mg, 2.65 mmol) and DMAP (22 mg). The 
resulting suspension was stirred at rt for about 4h, then the precipitate was removed by filtration and 
the filtrate was concentrated, to give 14 (966 mg, 2.14 mmol, 97 % yield) as a colorless oil: 1H-
NMR (CDCl3): δ 0.84 (d, 6H, J = 6.8 Hz, 2 CH3), 0.96-1.01 (m, 2H, CH2), 1.29-1.58 (m, 4H, CH2, 
2 CH), 1.50 (d, 3H, J = 6.4 Hz, CH3); 1.65-2.00 (m, 5H, 2 CH2, CH), 3.04-3.21 (m, 2H, CH2Ph), 
4.86-4.94 (m, 1H, CHNH), 5.06-5.19 (m, 3H, CH2O, CHOH), 5.89 (d, 1H, J = 7.9 Hz, NH), 6.95-
7.02 (m, 2H, Ar), 7.07-7.41 (m, 7H, Ar). Anal. (C28H37NO4) C, H, N. % Calcd: 74.47 (C); 8.26 (H); 
3.10 (N). % Found: 74.36 (C); 8.11 (H); 2.98 (N). 
 
 
4.1.15 4-[1-(chloroethyl]benzoate of nateglinide 15 
HClconc. (1.2 mL) was added at room temperature to a stirred suspension of 4-[1-
(hydroxyethyl]benzoate of nateglinide (14) (1.04 g, 2.31 mmol) in toluene (10 mL). The  resulting 
solution was stirred for 20h at room temperature. Then, the solvent was evaporated to afford 15 as a 
colorless oil (1.02 mg, 2.17 mmol, 94 % yield): 1H NMR (CDCl3): δ 0.83 (d, 6H, J = 6.6 Hz, 2 
CH3), 0.97-1.01 (m, 2H, CH2), 1.25-1.42 (m, 4H, CH2, 2 CH), 1.58-2.00 (m, 8H, 2 CH2, CH, CH3), 
3.10-3.24 (m, 2H, CH2Ph), 4.81-4.96 (m, 1H, CHNH), 5.04-5.20 (m, 3H, CH2O, CHCl), 5.94 (d, 
1H, J = 7.7 Hz, NH), 6.94-7.00 (m, 2H, Ar), 7.10-7.44 (m, 7H, Ar). Anal. (C28H36ClNO3) C, H, N. 
% Calcd: 71.55 (C); 7.72 (H); 2.98 (N). % Found: 71.68 (C); 7.84 (H); 3.09 (N). 
4.2 Pharmacology 
4.2.1 Evaluation of NO-releasing properties 
As a preliminary pharmacological investigation, the NO-mediated vasorelaxing effects of the 
synthesised compounds were evaluated by functional tests on isolated endothelium-denuded rat 
aortic rings. 
As concerns the vasorelaxing responses, increasing concentrations (10 nM – 30 µM) of the 
tested compounds were added cumulatively to aortic rings pre-contracted by KCl 30 mM. The 
index of potency was expressed as pIC50, representing the negative Logarithm of the concentration 
of the tested compound evoking an half-reduction of the contractile tone induced by KCl.  
The index of efficacy (Emax) indicated the maximal vasorelaxing response induced by the 
highest concentration (30µM) of the tested compounds and expressed as a % of the contractile tone 
induced by KCl. The pIC50 value could not be calculated for those compounds, exhibiting Emax < 
50%. The inhibition of guanylate cyclase by ODQ 1 µM was used as a tool to correlate the 
vasorelaxing activity with the release of NO.  
4.2.2 Evaluation of hypoglycaemic properties 
Male Wistar rats (250-300 g) were treated with streptozotocin (50 mg/Kg i.p.). After 4 days, 
animals showing a fasting glycaemic level of 100-150 mg/dl (representative of mild  type 2 
diabetes)  were used for the study. Normoglycaemic male Wistar rats (showing fasting glycaemia 
between 30 and 40 mg/dl) were used as reference animals. Diabetic animals were deprived of food 
for 24h, and then they received Nateglinide (50 mg/Kg, i.p.), or an equimolar dose of 4 (75.8 
mg/Kg i.p.) or vehicle. 10 min after  drug administration, the animals received glucose (1 g/Kg i.p.). 
While, normoglycaemic animals were deprived of food for 24h, and then they received only 
vehicle. 10 min after the drug or vehicle administration, all the animals received glucose (1 g/Kg 
i.p.).  The glycaemic levels were recorded for two h (at intervals of 0, 15, 30, 45, 60, 90 and 120 
min following the glucose administration) by tail puncture and the use of commonly used sensors 
(New Glucocard G sensor and Glucocard Gmeter, Arkray, A. Menarini diagnostics), and reported 
as increase from the basal one. The corresponding areas under curve (AUC) were also calculated. 
 4.2.3. Evaluation of cardio-protective anti-ischemic effects 
Male Wistar rats (250-300 g) were treated with streptozotocin (50 mg/Kg i.p.). After 4 days, 
animals showing a fasting glycaemic level of 100-150 mg/dl (representative of mild  type 2 
diabetes)  were used for the study. 11 days after the administration of streptozotocin, diabetic 
animals were treated with  Nateglinide (12  mg/Kg/day, i.p.), or an equimolar dose of 4 (18.2 
mg/Kg/day i.p.) or vehicle, for 7 days. Vehicle-treated normoglycaemic male Wistar rats  (showing 
fasting glycaemia between 30 and 40 mg/dl) were used as reference animals. On the day of the 
experiment, the animals were heparinised and anaesthetised with sodium penthobarbital. The hearts 
were rapidly removed and perfused in a Langendorff apparatus. After 30 min of equilibration time, 
the hearts were submitted to a ischemia/reperfusion cycle (30 min and 120 min, respectively). The 
inotropic and chronotropic parameters were monitored with a latex balloon inserted in the left 
ventricle through the mitral valve and expressed as rate pressure product (RPP = left ventricle 
developed pressure x heart rate). The RPP value recorded at the end of reperfusion (120th min) is 
reported as a % of the pre-ischemic one.  After 120 min of reperfusion, 2 mm-wide slices of left 
ventricles were treated with triphenyltetrazolium chloride, in order to allow a planimetric evaluation 
of damaged areas, expressed as ischemic area % of the whole area  (Ai/Atot). 
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Legends 
 
Figure 1 –General structures of multifunctional NO-donor/ insuline secretagogue derivatives NO-
Rep and NO-Nat 
 
Figure 2 -  (a) Vasorelaxing Effect (%) of 4 alone and in the presence of ODQ. (b) Hypoglycaemic 
effects of 4. Non-fasting glycaemic levels recorded in normoglycaemic animals and in 
streptozotocin-induced diabetic rats after intraperitoneal administration of Nateglinide (50 mg/Kg, 
i.p.), or an equimolar dose of 4 (75.8 mg/Kg i.p.) or vehicle. 
 
Figure 3 – (a) Functional recovery (RPP %) and (b) morphological evidence of myocardial injury 
(Ai/Avs %) recorded in Langendorff-perfused hearts exposed to ischemia-reperfusion. The hearts 
were isolated from normoglycaemic and diabetic rats, submitted to different pharmacological 
treatments. The data are expressed as mean ± SEM. 
 
Scheme 1 – Synthetic route for the preparation of the NO-releasing/insulin secretagogues hybrids 
1-4 
 
Scheme 2 – Synthetic route for the preparation of the NO-releasing/meglinides hybrids 5-7 
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aReagents and Conditions: (a) DCC, DMAP, 
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aReagents and Conditions: (a) LiAlH4 1M, THF, 0°C (yield > 90%); (b) DCC, DMAP, DCM, 3h,rt (yield > 90%); (c) 
HCl  ,20h, rt (yield: 60-80%); (d) AgNO , MeCN, 4h, rt (yield 16-25%)   
 
 
 
 
 
 
 
 
 
Table 1.   
The NO-mediated vasorelaxing efficacy (Emax%) and potency values (pIC50) of 1-7. The 
parameters of efficacy and potency are expressed as mean ± SEM. 
  
 
 
 
 
 
 
 
 
 
aThe pIC50 value was not calculable (n.c.) because of the low vasorelaxing efficacy (lower than 50%). 
 
 
Compd pIC50 Emax  
1 4.88 ± 0.03 79 ± 4 
2 5.09 ± 0.03 94 ± 1 
3 n.c.a 45 ± 2 
4 5.30 ± 0.04 93 ± 4 
5 n.c.a 26 ± 6 
6 5.30 ± 0.04 84 ± 3 
7 4.63 ± 0.03 58 ± 6 
